-

Thermo Fisher Scientific Awarded $94.5 Million U.S. Government Contract to Supply the Navy with Advanced Radiation Detection Systems

Next generation dosimetry system with advanced radiation health and database management software will help keep Navy personnel safe from harmful radiation exposure

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software.

The U.S. Navy operates the world’s most technologically advanced naval fleet and is the largest defense user of dosimetry systems globally. With this award, Thermo Fisher will supply Navy Occupational Dosimetry System (NODS) devices along with Navy Radiation Exposure Management System (NAVREMS) software. Manufactured in Oakwood Village, Ohio, these tools support the monitoring and management of occupational radiation exposure for Naval personnel associated with nuclear-powered Navy assets, nuclear-capable shipyards, research sites, laboratories, and naval medical facilities. The advanced digital dosimetry devices, featuring integrated beta, gamma, and neutron detection capabilities, are designed to deliver precise and reliable radiation exposure monitoring.

"We are honored to work with the U.S. Navy to help safeguard the health and safety of their personnel," said Rich McCartney, president of chemical analysis at Thermo Fisher Scientific. “This contract underscores the Navy's trust in our ability to deliver cutting-edge dosimetry technology and data management solutions. Our next-generation systems are purpose-built to provide precise, real-time radiation monitoring in the most demanding environments.”

Thermo Fisher is dedicated to providing customers with accurate chemical and radiation monitoring solutions to support safer working environments across fields like defense, healthcare, and industrial markets. This contract with the U.S. Navy marks a significant milestone in our ongoing efforts to support critical defense and safety operations.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Jesse Stivender, Thermo Fisher Scientific
510-299-4720
jesse.stivender@thermofisher.com

Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Jesse Stivender, Thermo Fisher Scientific
510-299-4720
jesse.stivender@thermofisher.com

Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand...

Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine

CARLSBAD, Calif.--(BUSINESS WIRE)--Today, Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus* is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows. CGP facilit...

Thermo Fisher Scientific Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world h...
Back to Newsroom